Blair William & Co. IL Sells 8,019 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Blair William & Co. IL lowered its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 417,894 shares of the company’s stock after selling 8,019 shares during the period. Blair William & Co. IL’s holdings in PROCEPT BioRobotics were worth $33,649,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new position in PROCEPT BioRobotics during the 4th quarter worth $207,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of PROCEPT BioRobotics by 292.8% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 36,860 shares of the company’s stock valued at $3,107,000 after acquiring an additional 27,475 shares in the last quarter. Segall Bryant & Hamill LLC grew its stake in shares of PROCEPT BioRobotics by 40.9% in the fourth quarter. Segall Bryant & Hamill LLC now owns 142,039 shares of the company’s stock valued at $11,437,000 after acquiring an additional 41,238 shares in the last quarter. Vanguard Group Inc. increased its position in PROCEPT BioRobotics by 6.1% during the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company’s stock worth $413,907,000 after acquiring an additional 297,075 shares during the period. Finally, LPL Financial LLC raised its stake in PROCEPT BioRobotics by 78.7% in the 4th quarter. LPL Financial LLC now owns 9,441 shares of the company’s stock worth $760,000 after purchasing an additional 4,157 shares in the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Stock Down 0.9 %

Shares of PRCT opened at $61.76 on Friday. The firm has a 50 day simple moving average of $65.66 and a two-hundred day simple moving average of $77.93. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a one year low of $45.56 and a one year high of $103.81. The company has a market cap of $3.39 billion, a P/E ratio of -31.67 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million during the quarter, compared to the consensus estimate of $66.79 million. Research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now directly owns 107,991 shares of the company’s stock, valued at approximately $6,161,966.46. The trade was a 0.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the transaction, the chief executive officer now owns 173,070 shares of the company’s stock, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Wells Fargo & Company reaffirmed an “overweight” rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Morgan Stanley reduced their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $90.00 price objective (down from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.29.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).